GLAXF — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
$24.95
Market Cap
$99.94B
52W High
$27.18
52W Low
$23.46
ADV30
727
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
| Sep 2025 | 8,547,000,000 | 6,289,000,000 | 2,593,000,000 | 2,013,000,000 | 61,339,000,000 | 3,296,000,000 | 45,587,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,737,000,000
Investing CF
$-4,555,000,000
Financing CF
$-4,271,000,000
CapEx
$-2,980,000,000
Dividends Paid
$-2,595,000,000
Buybacks
$-1,456,000,000
EPS Diluted TTM
$1.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$11,590,000,000
Inventory
$6,157,000,000
Receivables
—
ST Investments
$1,000,000
EBIT TTM
$8,129,000,000
Pretax Income TTM
$7,437,000,000
Interest Exp TTM
$692,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$114,693,652,480
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
4,005,611,246
Trailing EPS
$1.57
Book Value
$5.89
ROE
33.4%
ROA
10.0%
Div Yield
3.62%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,118,000,000 | 45,162,000,000 | — | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,463,000,000 | 46,377,000,000 | — | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,005,000,000 | 46,210,000,000 | — | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,146,000,000 | 50,050,000,000 | — | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNYNF | Sanofi | $100.48B | $83.87 | — |
| SNY | Sanofi | $103.23B | $43.08 | — |
| GSK | GSK plc | $103.53B | $51.69 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $121.09B | $477.10 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $77.13B | $762.63 | — |
News headlines (Yahoo Finance, 1h cache)
GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics
2026-08-01 06:15 · Yahoo
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
2026-07-30 17:46 · Yahoo
Chandigarh University's Biotechnology & Pharmacy Students Secure 178 Placements with Leading Pharmaceutical and Biotechnology Companies
2026-07-30 12:57 · Yahoo
GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...
2026-07-30 01:03 · Yahoo
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
2026-07-29 17:03 · Yahoo
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
2026-07-29 15:52 · Yahoo
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
2026-07-29 14:56 · Yahoo
GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline
2026-07-28 19:51 · Yahoo
GSK Q2 Earnings Call Highlights
2026-07-28 18:04 · Yahoo
GSK plots £400m Cambridge research hub in push for cancer breakthrough
2026-07-28 14:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.